These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 32073423)

  • 1. Cannabidiol as a treatment option for schizophrenia: recent evidence and current studies.
    Schoevers J; Leweke JE; Leweke FM
    Curr Opin Psychiatry; 2020 May; 33(3):185-191. PubMed ID: 32073423
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A systematic review of the antipsychotic properties of cannabidiol in humans.
    Iseger TA; Bossong MG
    Schizophr Res; 2015 Mar; 162(1-3):153-61. PubMed ID: 25667194
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cannabidiol and Sodium Nitroprusside: Two Novel Neuromodulatory Pharmacological Interventions to Treat and Prevent Psychosis.
    Crippa JA; Hallak JE; Abílio VC; de Lacerda AL; Zuardi AW
    CNS Neurol Disord Drug Targets; 2015; 14(8):970-8. PubMed ID: 26350340
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effects of cannabidiol (CBD) on cognition and symptoms in outpatients with chronic schizophrenia a randomized placebo controlled trial.
    Boggs DL; Surti T; Gupta A; Gupta S; Niciu M; Pittman B; Schnakenberg Martin AM; Thurnauer H; Davies A; D'Souza DC; Ranganathan M
    Psychopharmacology (Berl); 2018 Jul; 235(7):1923-1932. PubMed ID: 29619533
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cannabidiol as a potential treatment for psychosis.
    Schubart CD; Sommer IE; Fusar-Poli P; de Witte L; Kahn RS; Boks MP
    Eur Neuropsychopharmacol; 2014 Jan; 24(1):51-64. PubMed ID: 24309088
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cannabidiol versus risperidone for treatment of recent-onset psychosis with comorbid cannabis use: study protocol for a randomized controlled clinical trial.
    Rasmussen JØ; Jennum P; Linnet K; Glenthøj BY; Baandrup L
    BMC Psychiatry; 2021 Aug; 21(1):404. PubMed ID: 34391393
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic Potential of Cannabinoids in Psychosis.
    Leweke FM; Mueller JK; Lange B; Rohleder C
    Biol Psychiatry; 2016 Apr; 79(7):604-12. PubMed ID: 26852073
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cannabidiol modulation of hippocampal glutamate in early psychosis.
    O'Neill A; Annibale L; Blest-Hopley G; Wilson R; Giampietro V; Bhattacharyya S
    J Psychopharmacol; 2021 Jul; 35(7):814-822. PubMed ID: 33860709
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of cannabidiol in a MK-801-rodent model of aspects of schizophrenia.
    Gururajan A; Taylor DA; Malone DT
    Behav Brain Res; 2011 Sep; 222(2):299-308. PubMed ID: 21458498
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Potential of Cannabidiol Treatment for Cannabis Users With Recent-Onset Psychosis.
    Hahn B
    Schizophr Bull; 2018 Jan; 44(1):46-53. PubMed ID: 29083450
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Medical use of cannabis. Cannabidiol: a new light for schizophrenia?
    Deiana S
    Drug Test Anal; 2013 Jan; 5(1):46-51. PubMed ID: 23109356
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia.
    Leweke FM; Piomelli D; Pahlisch F; Muhl D; Gerth CW; Hoyer C; Klosterkötter J; Hellmich M; Koethe D
    Transl Psychiatry; 2012 Mar; 2(3):e94. PubMed ID: 22832859
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Decreased glial reactivity could be involved in the antipsychotic-like effect of cannabidiol.
    Gomes FV; Llorente R; Del Bel EA; Viveros MP; López-Gallardo M; Guimarães FS
    Schizophr Res; 2015 May; 164(1-3):155-63. PubMed ID: 25680767
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Is cannabidiol an effective treatment for schizophrenia?
    Guinguis R; Ruiz MI; Rada G
    Medwave; 2017 Aug; 17(7):e7010. PubMed ID: 28820868
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cannabidiol monotherapy for treatment-resistant schizophrenia.
    Zuardi AW; Hallak JE; Dursun SM; Morais SL; Sanches RF; Musty RE; Crippa JA
    J Psychopharmacol; 2006 Sep; 20(5):683-6. PubMed ID: 16401651
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cannabidiol, a Cannabis sativa constituent, as an antipsychotic drug.
    Zuardi AW; Crippa JA; Hallak JE; Moreira FA; Guimarães FS
    Braz J Med Biol Res; 2006 Apr; 39(4):421-9. PubMed ID: 16612464
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cannabidiol is a partial agonist at dopamine D2High receptors, predicting its antipsychotic clinical dose.
    Seeman P
    Transl Psychiatry; 2016 Oct; 6(10):e920. PubMed ID: 27754480
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of cannabidiol oil in schizophrenia treatment. a systematic review and meta-analysis.
    Kopelli E; Samara M; Siargkas A; Goulas A; Papazisis G; Chourdakis M
    Psychiatry Res; 2020 Sep; 291():113246. PubMed ID: 32599446
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aripiprazole: a review of its use in schizophrenia and schizoaffective disorder.
    Swainston Harrison T; Perry CM
    Drugs; 2004; 64(15):1715-36. PubMed ID: 15257633
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modafinil as an adjunctive treatment of sedation, negative symptoms, and cognition in schizophrenia: a critical review.
    Saavedra-Velez C; Yusim A; Anbarasan D; Lindenmayer JP
    J Clin Psychiatry; 2009 Jan; 70(1):104-12. PubMed ID: 19026265
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.